Home › Encyclopedia › Bradykinin: Research Status and Trial Data
Research / Unapproved

Bradykinin: Research Status and Trial Data

Molecular formulaC50H73N15O11
Molecular weight1060.2 g/mol
Registered trials150
PubChem CID439201

What bradykinin is

Bradykinin is a peptide compound identified by PubChem CID 439201, with a molecular formula of C50H73N15O11. It does not have an approved FDA label, and no drug product is currently authorized to contain it as an active ingredient. Research interest in bradykinin centers on its role in vascular and inflammatory signaling, as reflected in the studies registered around it.

Trial footprint

There are 150 registered clinical trials associated with bradykinin. Among the sampled studies, one completed Phase 3 trial examined the role of the angiotensin type I receptor in regulating human coronary vascular function. Another completed Phase 3 trial evaluated lanadelumab for preventing acute attacks of non-histaminergic angioedema with normal C1 inhibitor, a condition tied to bradykinin-related pathways. A separate study with no listed phase is investigating dry needling and shoulder muscle blood flow, motions, and pain sensitivity in individuals with shoulder pain, and remains active but not recruiting.

FAQ

Is bradykinin FDA approved?
No. Bradykinin does not have an FDA-approved label or authorized drug product. It is studied as a research compound rather than used as an approved medication.
What is bradykinin used for in research?
Bradykinin is studied in connection with vascular function, inflammatory pathways, and conditions involving angioedema. Trials referencing bradykinin-related mechanisms include studies on coronary vascular regulation and non-histaminergic angioedema.
How many clinical trials involve bradykinin?
There are 150 registered clinical trials associated with bradykinin. These span a range of research areas, including cardiovascular physiology and pain-related conditions.
Does bradykinin have any approved brand name products?
No. Since bradykinin lacks an FDA label, there are no approved brand names associated with it as a standalone drug product.
What is the chemical identity of bradykinin?
Bradykinin has the molecular formula C50H73N15O11 and a molecular weight of approximately 1060.2. It is cataloged in PubChem under CID 439201.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 439201 ClinicalTrials.gov

Updated 2026-11-07